Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Harrington K, Kitano S, Gambardella V, Parkes EE, Moreno I, Alonso G, Doi T, Berz D, Gutierrez ME, Fernandez N, Schmohl M, Barrueco J, LoRusso P.
Harrington K, et al. Among authors: alonso g.
Future Oncol. 2025 Jan 16:1-6. doi: 10.1080/14796694.2024.2441107. Online ahead of print.
Future Oncol. 2025.
PMID: 39817655
Free article.